Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Endocrinol Metab Clin North Am ; 50(2): 167-178, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-34023036

RESUMEN

Significant development has occurred in the treatment of postmenopausal osteoporosis. We review the most recent guidelines from the American Association of Clinical Endocrinologists/American College of Endocrinology, Endocrine Society, and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis/International Osteoporosis Foundation Guidelines.


Asunto(s)
Endocrinología , Osteoporosis Posmenopáusica , Osteoporosis , Densidad Ósea , Endocrinólogos , Femenino , Humanos , Osteoporosis/diagnóstico , Osteoporosis/tratamiento farmacológico , Osteoporosis/etiología , Osteoporosis Posmenopáusica/tratamiento farmacológico , Medición de Riesgo , Estados Unidos
2.
Fed Pract ; 33(Suppl 4): 37S-43S, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-30766218

RESUMEN

Increasing evidence, albeit small, suggests that testosterone replacement therapy can be cautiously considered in selected hypogonadal men treated with curative intent for low-risk prostate cancer and without evidence of active disease.

3.
Womens Health (Lond) ; 11(4): 477-82; quiz 483-4, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26236988

RESUMEN

Osteoporosis, a well-defined and growing public health problem, is a disease characterized by increased bone turnover and decreased bone mass with associated skeletal fragility, resulting in an increased risk of fracture. It is often unrecognized until the late stages when fragility fractures have occurred. In adults, early recognition of the disease prior to the occurrence of fractures followed by timely and efficient initiation of appropriate treatment can reduce fracture risk. In this article, we review clinical modalities available to effectively predict fracture risk in patients with osteoporosis. Bone mineral density and presence of clinical risk factors may be combined to provide a more comprehensive osteoporotic fracture risk assessment. Use of FRAX may serve as a general guideline for clinical management and deciding a threshold for cost-effective pharmacological intervention. Elevated bone turnover markers are predictive of high fracture risk and can provide additional clinical information as well.


Asunto(s)
Densidad Ósea , Fracturas Osteoporóticas/epidemiología , Fracturas Osteoporóticas/fisiopatología , Factores de Edad , Anciano , Anciano de 80 o más Años , Biomarcadores , Índice de Masa Corporal , Remodelación Ósea/fisiología , Comorbilidad , Femenino , Conductas Relacionadas con la Salud , Humanos , Estilo de Vida , Masculino , Persona de Mediana Edad , Factores de Riesgo
4.
J Neurosci Res ; 69(5): 692-5, 2002 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-12210836

RESUMEN

Metabolite levels in cerebrospinal fluid from patients with lower back pain and/or sciatica caused by disc herniation or spinal stenosis were compared with levels in pain-free controls using proton magnetic resonance spectroscopy. Significant differences for several metabolites were found in patients with pain compared with controls. Most changes were found in the group with disc herniation, including reductions in glucose, alanine, and lactate, suggesting increased aerobic metabolism in this group. There was a significant reduction in the level of glucose in the group with spinal stenosis irrespective of whether the patients were compared with the whole control group (age-weighted) or with age-matched controls. Additionally, inositol and creatinine were reduced in patients with disc herniation. Inositol was also significantly reduced in the spinal stenosis group when age matched to controls. Insofar as the levels of pain recorded by the patients with lumbar pathology were similar in the two groups, it seems more likely that the reductions in metabolite levels recorded in the group with disc herniations are related to disc pathology rather than the perception of pain. However, the possibility that pain perception contributes to the metabolic changes cannot be excluded.


Asunto(s)
Líquido Cefalorraquídeo/metabolismo , Desplazamiento del Disco Intervertebral/líquido cefalorraquídeo , Estenosis Espinal/líquido cefalorraquídeo , Adolescente , Adulto , Anciano , Análisis de Varianza , Creatinina/líquido cefalorraquídeo , Femenino , Glucosa/líquido cefalorraquídeo , Humanos , Inositol/líquido cefalorraquídeo , Lactatos/líquido cefalorraquídeo , Espectroscopía de Resonancia Magnética , Masculino , Persona de Mediana Edad , Dolor/líquido cefalorraquídeo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...